Granted Patent B2

US 12,629,344 · App. 18/277,679 · Granted May 19, 2026

Inventors: Eva-Marie Prinz (Weißenthurm, DE); Marco Emgenbroich (Rheinbach, DE); Birgit Braun (Wied, DE); Peter Bohnenkämper (Horhausen, DE)

Assignee: LTS LOHMANN THERAPIE-SYSTEME AG

A61K9/7084A61K31/658A61K47/10A61K47/14A61K47/32A61K47/34

Abstract

Claims (20)

1 . A transdermal therapeutic system comprising

i) an active agent impermeable backing layer, ii) at least one adhesive layer comprising at least 70% by weight of at least two polysiloxane polymer, at least one tetrahydrocannabinol (THC) and at least one solubilizer, and optionally iii) a protective layer for removal before use, wherein the at least one solubilizer is selected from the group consisting of polyvinylpyrrolidone, pentanoic acid, capric acid, caprylic acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, linoleic acid, lignoceric acid, isoverlic acid, neoheptonic acid, neonanonic acid, isostearic acid, pentanoic acid, hexanoic acid, ricinoleic acid, octanoic acid, nonanoic acid, decanoic acid, lauric acid, oleic acid, arachidonic acid, galloleic acid, erucic acid, polyethylene glycol monolaureate, PEG-6 mono- and diesters of oleic acid, polyethylene glycol dodecyl ether/polyoxyethylene(4)lauryl ether, a polyvinylcaprolactam-/polyvinylacetate-/polyethyleneglycol-copolymer, wherein the polysiloxane polymers are amine-resistant, and wherein the adhesive layer comprises a mixture of a high-tack and a medium or low-tack silicone polymer.

2 . Transdermal therapeutic system according to claim 1 , wherein the polysiloxane is self-adhesive.

3 . Transdermal therapeutic system according to claim 1 , wherein the at least one tetrahydrocannabinol is selected from Δ8-tetrahydrocannabinol, Δ9-tetrahydrocannabinol and R-(6a,10a)-Δ9-tetrahydrocannabinol.

4 . Transdermal therapeutic system according to claim 1 , wherein the at least one tetrahydrocannabinol is present in an amount from 0.1 to 20% by weight based on the total weight of the at least one adhesive layer.

5 . Transdermal therapeutic system according to claim 1 , wherein C2 to C20 saturated or unsaturated aliphatic carboxylic acids are excluded as solubilizer.

6 . Transdermal therapeutic system according to claim 1 , wherein the at least one solubilizer is present in an amount from 0.1 to 12% by weight based on the total weight of the at least one adhesive layer.

7 . Transdermal therapeutic system according to claim 1 , further comprising at least one permeation enhancer.

8 . Transdermal therapeutic system according to claim 6 , wherein the at least one permeation enhancer is selected from the group consisting of PEG-6 apricot kernel oil, propylene glycol, 2-(2-ethoxyethoxy)ethanol.

9 . Transdermal therapeutic system according to claim 1 , wherein the transdermal therapeutic system does not contain a compound having an HLB of 6 or more.

10 . Transdermal therapeutic system according to claim 1 , further comprising at least one antioxidant.

11 . A method for preparing a transdermal therapeutic system according to claim 1 , comprising the steps of:

a) preparing a mixture comprising at least two polysiloxane polymer, at least one tetrahydrocannabinol and at least one solubilizer;

b) applying the mixture of a) on a protective layer for removal before use, and

c) applying an active agent impermeable backing layer on the layer of the mixture prepared in step b).

12 . Transdermal therapeutic system according to claim 1 for use as a medicament.

13 . Transdermal therapeutic system according to claim 10 , wherein the at least one antioxidant comprises tocopherol, ascorbyl palmiate, ascorbic acid, butylhydroxytoluol, or a combination of thereof.

14 . Transdermal therapeutic system according to claim 12 , wherein the medicament is effective in the treatment of nausea, vomiting, neuropathic pain, fibromyalgia, anorexia, cachexia, multiple sclerosis, traumatic cross-sectional disorders, dystonic movement disorders, asthma bronchiale, epileptic seizures, withdrawal symptoms in alcohol, benzodiazepine and opiate addiction, Parkinson's disease, dementia, Alzheimer's disease, arthritis, glaucoma, migraine, dysmenorrhea or Tourette syndrome.

15 . A transdermal therapeutic system comprising

i) an active agent impermeable backing layer, ii) at least one adhesive layer comprising at least 70% by weight of at least two polysiloxane polymer, at least one tetrahydrocannabinol (THC) and at least one solubilizer, and iii) a protective layer for removal before use, wherein the at least one solubilizer is selected from the group consisting of polyvinylpyrrolidone, pentanoic acid, capric acid, caprylic acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, linoleic acid, lignoceric acid, isoverlic acid, neoheptonic acid, neonanonic acid, isostearic acid, pentanoic acid, hexanoic acid, ricinoleic acid, octanoic acid, nonanoic acid, decanoic acid, lauric acid, oleic acid, arachidonic acid, galloleic acid, erucic acid, polyethylene glycol monolaureate, PEG-6 mono- and diesters of oleic acid, polyethylene glycol dodecyl ether/polyoxyethylene(4)lauryl ether, a polyvinylcaprolactam-/polyvinylacetate-/polyethyleneglycol-copolymer, wherein the polysiloxane polymers are amine-resistant, and wherein the adhesive layer comprises a mixture of a high-tack and a medium or low-tack silicone polymer.

Assignments (1)

Priority Claims (1)

Continuity (2)

References Cited (30)